This acquisition enables ESTEVE CDMO (Esteve Química) to expand its contract development and manufacturing services for small-molecule active pharmaceutical ingredients
Total revenues for the second quarter 2025 increased 11% to $67.2 billion Shareholders' net income for the second quarter 2025
SHENZHEN, China, July 31, 2025 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences") announced that its wholly owned subsidiary,
TAMPA, Fla., July 31, 2025 /PRNewswire/ -- Joseph Spine Institute is proud to announce that its founder, Dr. Samuel A.
Esta adquisición permite a ESTEVE ampliar su oferta de servicios de desarrollo y fabricación por contrato de ingredientes farmacéuticos activos